Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple-ascending-dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of R1511 in Type 2 Diabetic (T2D) Patients

NCT00517465 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00517465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00517465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple-ascending-dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of R1511 in Type 2 Diabetic (T2D) Patients
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2007
Completion date
March 31, 2009
Enrollment
41 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2